Biotechnology Company Purissima Releases Study Findings Related to the Potential Applications and Usage of Cannabichromene (CBC)
Purissima, a leading biotechnology health and wellness company, announced the completion of two separate ingredient testing programs with two leading contract research organizations. Testing included biological tests on human skin explants to reveal the effectiveness of Purissima's produced compounds Cannabichromene (CBC) and Cannabichromenic acid (CBCA).
Purissima Announces Multi-Year Processing And Distribution Partnership With Open Book Extracts
Purissima is the first biotechnology company to achieve commercial scale production of minor cannabinoids using algae fermentation. In collaboration with Open Book Extracts, the company will officially commercialize before Fall 2022.
Leading Biotechnology Company Purissima Showcases First Ever Commercial Scale Production of Cannabinoids Using Algae Fermentation
The company has proven the capacity to produce more than 70 compounds, many of which are hard to replicate minor cannabinoids as well as new plant-powered chemistries with high potential therapeutic value.
BioTech Company Purissima Underscores Microalgae’s Capability To Sustainably Produce Pure, Topical Ingredient Alternatives As Global Cannabinoid Demand Is Projected To Reach Over $400B by 2025
Businesses will inevitably rely on innovators like Purissima to offer pure and sustainable ingredients while accounting for scalability, product consistency, and resource traceability.
Biotechnology Leader Purissima Receives Three New U.S. Patents
Further validates the platform’s technology advances in the fast-growing bioengineering industry.